Black Diamond Therapeutics, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. Clinical-stage oncology company; quarter ended March 31, 2024. It has no approved products and has generated no product revenue. Its two clinical-stage programs are BDTX-1535, an EGFR inhibitor, and BDTX-4933, a RAF inhibitor.
Financial performance and position
- Revenue: None. Profit margins are not meaningful because the company has no revenue.
- Operating expenses: $20.2 million, down $1.3 million from $21.6 million in Q1 2023. R&D was $13.5 million (down $1.2 million); G&A was $6.7 million (down $0.1 million).
- Net loss: $18.2 million, versus $20.9 million; basic and diluted loss per share was $0.35, versus $0.57. The improvement reflects lower operating expenses and higher other income.
- Cash flow: $21.2 million used in operating activities, compared with $20.0 million used in Q1 2023. Financing provided $4.1 million, including $4.0 million in net ATM proceeds. Investing activities used $13.7 million, primarily reflecting net investment purchases.
- Liquidity: Cash and cash equivalents of $25.4 million and investments of $89.8 million, totaling $115.2 million at quarter-end. Total current liabilities were $16.9 million; total liabilities were $38.2 million, including $24.5 million in operating lease liabilities. No borrowings or debt are reported in the supplied filing text.
- Equity: Accumulated deficit was $435.7 million; stockholders’ equity was $104.3 million. Quarter-end common shares outstanding were 52.5 million.
Material changes and notable items
- BDTX-1535 R&D spending increased $2.0 million as its clinical trial advanced; this was more than offset by a $2.2 million reduction in other research-program and platform spending and lower personnel costs.
- Other income was $2.0 million, versus $0.7 million. Management attributed the increase primarily to investment accretion.
- After quarter-end, the company sold 1.0 million shares through the ATM in April for $5.3 million net and 2.69 million shares in May for $15.3 million net, providing additional capital while increasing share count.
- Unrealized investment losses were $0.1 million in Q1 2024, versus unrealized gains of $0.6 million in Q1 2023.
Outlook, commentary, and risks
- Management estimated that quarter-end cash, cash equivalents and investments would fund operations into Q3 2025. The filing also states the resources were expected to cover at least 12 months from the May 9, 2024 financial-statement issuance date. Both estimates depend on assumptions and could prove shorter than expected.
- The company expects continuing operating losses, increased expenses as clinical development progresses, and a need for substantial additional funding. Further financing may dilute shareholders; if funding is unavailable on acceptable terms, it may delay, reduce or discontinue programs.
- Management expected BDTX-1535 second- and third-line NSCLC cohort results in Q3 2024 and first-line cohort results in Q1 2025. A BDTX-4933 trial update was anticipated in Q4 2024. The company planned to present BDTX-1535 glioma data at ASCO on June 1, 2024.
- Management reported BDTX-1535 Phase 1 NSCLC clinical responses and described the candidate as generally well tolerated in prior GBM dose escalation, with no new safety signals observed. BDTX-4933 was in Phase 1 dose escalation; efficacy and safety outcomes remain uncertain.
- The company was evaluating strategic alternatives for BDTX-4876 and another preclinical program. Development, regulatory, enrollment, manufacturing, intellectual-property, competition and capital-market risks could affect timelines, funding needs and outcomes.
- Contract research and other service agreements are generally cancelable, but cancellation can require payment for services rendered and certain incurred obligations. License milestone and royalty payments are contingent and not reasonably estimable. The company reported no material legal proceedings.
Important facts for investors to verify
- Whether clinical trial results and stated update timelines for BDTX-1535 and BDTX-4933 are achieved, and what the full efficacy and safety data show.
- Whether the Q3 2025 runway estimate remains achievable after operating cash use and subsequent ATM share sales, and when additional financing may be required.
- The effects of the April and May ATM issuances, future share sales and equity-award dilution on ownership and per-share value.
- Progress and any terms or consequences of strategic alternatives for BDTX-4876 and the other preclinical program.
- The size and timing of future lease, licensing, clinical-development and other commitments, including contingencies that are not currently estimable.